Efimosfermin alfa
Based on 1 Customer Validation
Efimosfermin alfa is a genetically engineered FGF21 variant. Efimosfermin alfa exerts its function by activating the FGFR1c/β-Klotho complex. Efimosfermin alfa is applicable to researches on metabolic dysfunction-associated steatohepatitis, obesity and mild hypertriglyceridemia.
For research use only. We do not sell to patients.
- Purity : 99%
- CAS No.: 2765640-39-7
- Molecular Weight:89.11 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Species Reactivity
Human
In Vitro
Efimosfermin alfa works by activating the FGFR1c/β-Klotho complex.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
FPIA_FC-[PROTEIN]2
Verified Bioactivity
-
Measured in a cell proliferation assay using NIH-3T3 mouse embryonic fibroblast cells. The ED50 for this effect is 0.3816 μg/mL in the presence of 1.25μg/mL Klotho beta, corresponding to a specific activity is 2.62×10^3 units/mg.
Chemical Information
-
CAS No. 2765640-39-7
-
Appearance Liquid
-
Molecular Weight 89.11 kDa
-
Color Colorless to light yellow
-
SMILES
[Efimosfermin alfa]
-
Synonyms
BOS-580; LLF580
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Loomba R, et al. Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2025;10(8):734-745. [Content Brief]
[2]. Cui X, et al. Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment. Front Pharmacol. 2025 Apr 22;16:1510322. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)